+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 30Years - 85Years
All Genders
Healthy Volunteers
ID06809400

Evaluating the Safety, Tolerability, and Pharmacokinetics of Intravenous LY4006896 Compared to Placebo in Healthy Adults and Parkinsons Disease Patients

Led by Eli Lilly and Company · Updated on 2026-10-14

90

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and behavior of LY4006896 when given intravenously to healthy adults and people with Parkinsons disease. This study compares LY4006896 with a placebo to understand how the drug interacts with the body and its effects over time. The study includes both healthy volunteers and participants diagnosed with Parkinsons disease, aiming to collect important safety and pharmacokinetic data. Participants with Parkinsons disease will undergo up to four doses of LY4006896 or placebo during a screening period lasting up to 120 days, followed by treatment and follow-up lasting up to 61 weeks. Healthy participants will receive a single escalating dose or placebo in a screening period lasting up to 35 days and be followed for up to 48 weeks. The study involves random assignment to receive either LY4006896 or placebo, with single blinding to ensure unbiased results. Throughout the study, participants will have regular assessments including monitoring for serious or treatment-emergent adverse events, blood sampling for drug concentration measurement, and evaluations of Parkinsons disease-related markers such as alpha-synuclein in skin and cerebrospinal fluid. Participants will be followed for up to 78 weeks Parkinsons group or 53 weeks healthy group to evaluate safety and drug effects. The trial includes detailed cognitive assessments and eligibility screening to ensure participant safety and data reliability.

CONDITIONS

Brief Title

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here